In recent years, with increasing prevalence, particularly in young patients, breast cancer is considered to be one of the most common malignancies. The aim of the present study was to evaluate the clinical value of digital breast tomosynthesis (DBT) in diagnosing molecular subtypes of breast cancer. The present study retrospectively analyzed 134 cases of breast cancer with data regarding surgery, complete pathology and immunohistochemistry, which were collected at The Second Clinical College of Fujian Medical University (Quanzhou, China) between May 2013 and October 2014. The patients were divided into the four following molecular subtypes: Luminal A, luminal B, triple-negative and human epidermal growth factor receptor 2 (HER-2) overexpression, according to the expression of estrogen receptor, progesterone hormone receptor, HER-2 and Ki67. The association between clinical characteristics of each molecular subtype and characteristics of DBT were assessed. Calcification scores and lymph node size were the indicators that exhibited a significant difference following comparison between the four molecular subtypes. The subgroup analysis based on tumor size, calcification scores and lymph node size identified a significant difference in the distribution between patients with breast cancer with lymph node size of ≥1.5 and <1.5 cm. The analysis also revealed that the molecular subtypes of breast cancer were significantly associated with variables of calcification scores and lymph node size. In conclusion, the diagnostic imaging features, including calcification score and lymph node size, determined using DBT could be used as assistant diagnostic markers of breast cancer molecular subtypes.
Objective This study is to explore the correlation between the contrast-enhanced ultrasound (CEUS) characteristics of breast cancer and the epithelial-mesenchyme transformation (EMT). Methods Totally 119 patients of breast cancer underwent CEUS. Tissues in the active area were collected and subjected to the immunohistochemical detection, PT-PCR and Western blot. Correlation analysis was conducted between the clinical pathological parameters and the CEUS indicators. Results The expression levels of CD44, N-cadherin, and β-catenin in breast cancer tissues were higher than those in adjacent tissues (P<0.05). However, the expression levels of CD24 and E-cadherin in breast cancer tissues were lower than those in adjacent tissues (P<0.05). There was no significant difference in E-cadherin mRNA and Vimentin levels between cancer and adjacent tissues (P>0.05). The expressions were up-regulated in the CSCs, with higher histological grade, lymph node metastasis, and negative estrogen receptor (ER) expression. Smaller breast tumors, with no lymph node metastasis, lower clinical stage, and positive ER expression, tended to exhibit the up-regulated epithelial phenotype. Breast tumors, with high histological grade, lymph node metastasis, high clinical staging grade, and negative ER expression, tended to exhibit the up-regulated interstitial phenotype. The peak intensity of the time-intensity curve (TIC) for the CEUS was positively correlated with the CSC marker CD44 and the interstitial phenotype marker N-cadherin. The starting time of enhancement was negatively correlated with the N-cadherin. Area under the curve was positively correlated with the expression of CD44 and N-cadherin, while negatively correlated with the epithelial phenotype marker β-catenin. The time to peak was negatively correlated with the interstitial phenotypes Vimentin and N-cadherin, with no correlation with the E-cadherin or β-catenin. Conclusion Breast cancers show the enlarged lesions after enlargement and perfusion defect for the CEUS. The fast-in pattern, high enhancement, and high perfusion in the TIC are correlated with the CSCs and EMT expressions, suggesting poor disease prognosis.
subsequent infusions in patients with no serious complications from their first infusion. Rapid infusion of rituximab has been shown to be generally well-tolerated, with an IRR rate of 8.8% reported in a recent meta analysis (Polwart, 2017); however, there are limited data on the safety of rapid infusion of CT-P10. Aims: To evaluate the safety and effectiveness of rapidly infused CT-P10 in patients with NHL or CLL in a real world clinical setting. Methods: This non-interventional post-authorisation safety study is in progress in four European countries (United Kingdom [UK], Spain, France, Italy) and involves collection of data from the medical records of consenting adult patients with NHL or CLL who received rapidly-infused CT-P10 (i.e. a total infusion time of 90 minutes or less) during standard clinical care. The index date (day 1) is the date of the first rapid CT-P10 infusion, given in the second or a subsequent treatment cycle. Safety and effectiveness data are being collected for a 6 month observation period from the index date (or to death, if sooner). The primary outcome is incidence of IRRs on day 1 or day 2 post-index. Response to CT-P10 is as documented by the local investigator. Interim results are presented, based on a data cut on 18 January 2019. Where n is less than the total number of patients, data were missing. Results: The interim analysis includes 110 patients enrolled from the UK and Spain. Ninety-eight patients (90%) have NHL (68 [62%] diffuse large B-cell lymphoma [DLBCL], 30 [28%] follicular lymphoma [FL]) and 11 (10%) have CLL (n = 1 diagnosis missing). Other patient characteristics at index date: 66 (60%) male; median age 68 years (interquartile range [IQR] 59-74) (n = 109); median disease duration 0.2 years (IQR 0.1-0.3) (n = 109); 22 (20%) patients with prior NHL/CLL treatment recorded (n = 109); Eastern Cooperative Oncology Group performance status (n = 71): 0 (n = 34, 48%), 1 (n = 27, 38%), 2 (n = 3, 8%), 3 (n = 6, 8%) or 4 (n = 1, 1%); Ann Arbor stage for NHL (n = 52): I (n = 4, 8%), II (n = 5, 10%), III (n = 7, 13%) or IV (n = 36, 69%); Binet stage for CLL (n = 7): A (n = 4, 57%), B (n = 1, 14%) or C (n = 2, 29%). Eight of 106 patients with data available (8%) had IRRs recorded on day 1 or 2 post-index. Ten IRRs were reported (fatigue [n = 3], oropharyngeal pain, vomiting, nausea, rash, headache, generalized oedema, peripheral oedema [all n = 1]), of which 8 were grade 1 (mild), 1 was grade 2 (moderate) and 1 was grade 3 (severe [oropharyngeal pain during cycle 2, unlikely to be related to CT-P10 according to local investigator opinion]). Best responses to CT-P10 during the observation period are shown in Fig. 1. Summary/Conclusion:This is the first multi-country study to investigate the safety and effectiveness of rapidly infused CT-P10 in a real world setting. Early results suggest that the IRR rate for rapidly infused CT-P10 is similar to rates previously reported for reference rituximab.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.